Bladder-sparing options for BCG-unresponsive non-muscle invasive bladder cancer have transformed since 2020, according to Saum Ghodoussipour, MD.
|Articles|September 11, 2009
- ONCOLOGY Vol 23 No 10
- Volume 23
- Issue 10
Degarelix for Advanced Prostate Cancer Gets Trade Name
Ferring Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the trade name Firmagon (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix.
Advertisement
Ferring Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved the trade name Firmagon (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix. Firmagon is a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. Since initial market introduction under the generic name degarelix, the drug has been used by more than 3,000 patients to fight their prostate cancer.
Firmagon is the exact same product as degarelix and carries the same National Drug Code (NDC).
Articles in this issue
about 17 years ago
Radical Prostatectomy Reigns Supremeabout 17 years ago
Gingerabout 17 years ago
More Questions About Neoadjuvant Chemotherapy in Lung Cancerabout 17 years ago
Neoadjuvant Chemotherapy for Resectable Non–Small-Cell Lung Cancerabout 17 years ago
Preoperative Therapy for Early-Stage NSCLC: Opportunities and Challengesabout 17 years ago
FDA Approves First Maintenance Drug Therapy for Advanced Lung Cancerabout 17 years ago
Accelerated Approval Granted for Bevacizumab in Glioblastomaabout 17 years ago
New Opioid Pain Reliever Approved With Required Risk-Reduction Planabout 17 years ago
FDA Extends Review of OfatumumabAdvertisement
Related to this article
ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Herbert Lepor, MD, discussed NYU Langone's 1,000th focal cryotherapy procedure, Andre De Shields' case, and why prostate cancer treatment is at a turning point.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5